✓ Translated by DotMD AI Clinical Council Source: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #41486656 ↗

Phase III Randomized Trial: [Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population] (N = 18)

Original Paper Title: “[Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population]”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 18
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Further, the incidence of neutropenia during the treatment observation period was lower in the maribavir arm than in the valganciclovir arm (22.2% vs 55.6% ) .
  • Study Design & Sample: Phase III Randomized Trial published in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (N = 18 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2025), this phase iii randomized trial evaluating 18 human participants investigated: Objective: This study aimed to compare the efficacy and safety of maribavir and valganciclovir in the treatment of asymptomatic cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) recipients. Key clinical takeaway: Further, the incidence of neutropenia during the treatment observation period was lower in the maribavir arm than in the valganciclovir arm (22.2% vs 55.6% ) .

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025-12-14; N = 18; Rigor 88/100): Further, the incidence of neutropenia during the treatment observation period was lower in the maribavir arm than in the valganciclovir arm (22.2% vs 55.6% ) .

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: valganciclovir → Rx: ganciclovir-sodium → Rx: ganciclovir → Condition: influenza-due-to-other-identified-influenza-virus-with-myocarditis → Condition: influenza-due-to-other-identified-influenza-virus-with-otitis-media →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41486656: Phase III Randomized Trial: [Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population] (N = 18)

3 of 3 Free Questions Remaining